Pyrrolotriazine kinase inhibitors

Details Pyrrolotriazine kinase inhibitors Pyrrolotriazine kinase inhibitors

2005-10-04

2005-10-04

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S183000

Reexamination Certificate

active

06951859

ABSTRACT:
The present invention provides compounds of formula I,and pharmaceutically acceptable salts thereof.The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

REFERENCES:
patent: 2003/0069244 (2003-04-01), Leftheris et al.
patent: WO 02/40486 (2002-05-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition, vol. 1, 1004-1010, 1996.
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Fan et al., Trend Pharmacol. Sci., vol. 16, pp. 57-66 (1995).
Folkman, Nature Medicine, vol. 1, pp. 27-31 (1995).
Cullinan-Bove et al., Endocrinology, vol. 133, pp. 829-837 (1993).
Senger et al., Cancer and Metastasis Reviews, vol. 12, pp. 303-324 (1993).
DeVries et al., Science, vol. 255, pp. 989-991 (1992).
Terman et al., Biochem. Biophys. Res. Comm., vol. 187, pp. 1579-1586 (1992).
Jakeman et al., Endocrionology, vol. 133, pp. 848-859 (1993).
Kolch et al., Breast Cancer Research and Treatment, vol. 36, pp. 139-155 (1995).
Connolly et al., J. Biol. Chem., vol. 264, pp. 20017-20024 (1989).
U.S. Appl. No. 10/289,010, filed Nov. 6, 2002, Godfrey et al., pending.
U.S. Appl. No. 09/573,829, filed May 18, 2000, Hant et al., pending.
U.S. Appl. No. 10/294,281, filed Nov. 14, 2002, Mastalerz et al., pending.
U.S. Appl. No. 10/623,171, filed Jul. 18, 2003, Bhide et al., pending.
U.S. Appl. No. 10/420,399, filed Apr. 22, 2003, Dyckman et al., pending.
U.S. Appl. No. 10/420,445, filed Apr. 22, 2003, Dyckman et al., pending.
U.S. Appl. No. 10/440,864, filed May 19, 2003, Das et al., pending.

Affiliated with

Also associated with

Rating

Pyrrolotriazine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolotriazine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolotriazine kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3457106